|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: HIST1H2AI |
Gene summary for HIST1H2AI |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | HIST1H2AI | Gene ID | 8329 |
| Gene name | H2A clustered histone 13 | |
| Gene Alias | H2A/c | |
| Cytomap | 6p22.1 | |
| Gene Type | protein-coding | GO ID | GO:0008150 | UniProtAcc | A4FTV9 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 8329 | HIST1H2AI | LZE4T | Human | Esophagus | ESCC | 4.53e-04 | 5.07e-01 | 0.0811 |
| 8329 | HIST1H2AI | LZE20T | Human | Esophagus | ESCC | 2.95e-06 | 2.40e-01 | 0.0662 |
| 8329 | HIST1H2AI | LZE21D1 | Human | Esophagus | HGIN | 2.75e-06 | 6.26e-01 | 0.0632 |
| 8329 | HIST1H2AI | LZE24T | Human | Esophagus | ESCC | 4.35e-08 | 3.04e-01 | 0.0596 |
| 8329 | HIST1H2AI | LZE21T | Human | Esophagus | ESCC | 1.16e-05 | 4.49e-01 | 0.0655 |
| 8329 | HIST1H2AI | LZE6T | Human | Esophagus | ESCC | 9.61e-05 | 2.35e-01 | 0.0845 |
| 8329 | HIST1H2AI | P1T-E | Human | Esophagus | ESCC | 7.43e-09 | 3.82e-01 | 0.0875 |
| 8329 | HIST1H2AI | P2T-E | Human | Esophagus | ESCC | 4.30e-10 | 2.27e-01 | 0.1177 |
| 8329 | HIST1H2AI | P4T-E | Human | Esophagus | ESCC | 3.48e-08 | 2.22e-01 | 0.1323 |
| 8329 | HIST1H2AI | P8T-E | Human | Esophagus | ESCC | 8.40e-04 | 1.49e-01 | 0.0889 |
| 8329 | HIST1H2AI | P9T-E | Human | Esophagus | ESCC | 4.01e-04 | 1.82e-01 | 0.1131 |
| 8329 | HIST1H2AI | P10T-E | Human | Esophagus | ESCC | 8.40e-04 | 1.44e-01 | 0.116 |
| 8329 | HIST1H2AI | P12T-E | Human | Esophagus | ESCC | 7.90e-03 | 1.06e-01 | 0.1122 |
| 8329 | HIST1H2AI | P15T-E | Human | Esophagus | ESCC | 1.35e-04 | 1.92e-01 | 0.1149 |
| 8329 | HIST1H2AI | P17T-E | Human | Esophagus | ESCC | 1.49e-05 | 3.15e-01 | 0.1278 |
| 8329 | HIST1H2AI | P20T-E | Human | Esophagus | ESCC | 2.72e-14 | 4.48e-01 | 0.1124 |
| 8329 | HIST1H2AI | P22T-E | Human | Esophagus | ESCC | 2.27e-21 | 7.10e-01 | 0.1236 |
| 8329 | HIST1H2AI | P23T-E | Human | Esophagus | ESCC | 6.53e-09 | 3.50e-01 | 0.108 |
| 8329 | HIST1H2AI | P24T-E | Human | Esophagus | ESCC | 3.75e-03 | 1.29e-01 | 0.1287 |
| 8329 | HIST1H2AI | P26T-E | Human | Esophagus | ESCC | 9.02e-11 | 3.04e-01 | 0.1276 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| HIST1H2AI | SNV | Missense_Mutation | c.333N>A | p.Asn111Lys | p.N111K | P0C0S8 | protein_coding | deleterious_low_confidence(0.04) | benign(0.18) | TCGA-A2-A25E-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | PD | |
| HIST1H2AI | SNV | Missense_Mutation | c.229N>T | p.Thr77Ser | p.T77S | P0C0S8 | protein_coding | tolerated_low_confidence(0.25) | benign(0.012) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| HIST1H2AI | SNV | Missense_Mutation | c.292C>A | p.Leu98Met | p.L98M | P0C0S8 | protein_coding | deleterious_low_confidence(0.02) | benign(0.343) | TCGA-C5-A1BN-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD | |
| HIST1H2AI | SNV | Missense_Mutation | c.34N>G | p.Arg12Gly | p.R12G | P0C0S8 | protein_coding | deleterious_low_confidence(0.04) | benign(0.231) | TCGA-HM-A4S6-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR | |
| HIST1H2AI | SNV | Missense_Mutation | novel | c.49N>G | p.Thr17Ala | p.T17A | P0C0S8 | protein_coding | deleterious_low_confidence(0.02) | benign(0) | TCGA-AA-3662-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | capecitabine | PR |
| HIST1H2AI | SNV | Missense_Mutation | novel | c.146N>T | p.Pro49Leu | p.P49L | P0C0S8 | protein_coding | deleterious_low_confidence(0.04) | probably_damaging(0.992) | TCGA-CA-6719-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| HIST1H2AI | SNV | Missense_Mutation | c.11N>A | p.Arg4His | p.R4H | P0C0S8 | protein_coding | tolerated_low_confidence(0.07) | benign(0.306) | TCGA-CM-4743-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Chemotherapy | capecitabine | SD | |
| HIST1H2AI | SNV | Missense_Mutation | novel | c.200N>T | p.Ala67Val | p.A67V | P0C0S8 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.916) | TCGA-A5-A2K3-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | SD |
| HIST1H2AI | SNV | Missense_Mutation | novel | c.356A>C | p.Lys119Thr | p.K119T | P0C0S8 | protein_coding | deleterious_low_confidence(0.04) | probably_damaging(0.909) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| HIST1H2AI | SNV | Missense_Mutation | c.34N>T | p.Arg12Cys | p.R12C | P0C0S8 | protein_coding | deleterious_low_confidence(0.03) | possibly_damaging(0.667) | TCGA-95-7948-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |